The Association Among Vitamin D, Insulin Resistance, and Obesity in Turkish Women

authors:

avatar Fatma Nihan Turhan Caglar 1 , * , avatar Nilgun Isiksacan 2 , avatar Nursel Kocamaz 3 , avatar Faruk Akturk 1

Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Cardiology Department, Istanbul, Turkey
Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Biochemistry Department, Istanbul, Turkey
Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Internal Medicine Department, Istanbul, Turkey

how to cite: Nihan Turhan Caglar F, Isiksacan N, Kocamaz N, Akturk F. The Association Among Vitamin D, Insulin Resistance, and Obesity in Turkish Women. Shiraz E-Med J. 2017;18(2):e44925. https://doi.org/10.17795/semj44925.

Abstract

Background:

Vitamin D deficiency is common in patients with body mass index (BMI) higher than 25 kg/m2. The aim of this study was to evaluate whether any correlation exists among 25 hydroxyvitamin D, BMI, and other biochemical parameters in Turkish women subjects.

Methods:

A total number of 31 subjects with BMI ≥ 25 kg/m2 were included. These patients were, subsequently, divided into 2 groups according to their BMI. Group 1 consisted of patients with BMI:25 - 34 kg/m2 and group 2 with BMI ≥ 35 kg/m2. Venous blood samples were collected from the subjects in a morning fasting state to measure serum Vit D levels. high performance liquid chromatography-mass spectrometry (HPLC-MS) method was used for Vit D measurement. The homeostatic model assessment (HOMA) was used to quantify insulin resistance (IR).

Results:

A total number of 15 subjects (46.9%) had BMI 25 - 34 kg/m2 (group 1) and 17 subjects had BMI ≥ 35 kg/m2 (group 2). Vit D levels were 24.82 ± 13.7 ng/mL in group 1 and 23.56 ± 12.31 ng/mL in group 2. Although Vit D levels were lower than normal limits in both groups, they were not statistically different among the groups (p 0.901). Although statistically insignificant, insulin levels were higher in group 2 than group 1 (19.68 ± 7.91 µU/mL vs 17.6 ± 12.02 µU/mL; P = 0.29) and insulin levels were negatively correlated with Vit D (r = -0,631; P = 0,002; P < 0,05). HOMA-IR levels were insignificantly higher in group 2 patients than group 1 patients (5.10 ± 2.89 vs 4.19 ± 3.35; P = 0.25). HOMA-IR was negatively correlated with Vit D (r = -0,456; P = 0.05).

Conclusions:

We demonstrated decreased Vit D levels and a negative correlation among serum insulin levels, HOMA-IR, and Vit D in Turkish obese women. Epidemiological studies, also, indicate that Vit D deficiency may be related with IR and the development of diabetes. Further studies are needed.

1. Background

Vitamin D (Vit D) is a lipid-soluble vitamin that was first recognized in the 1920s (1). Sir Edward Mellanby observed Rickets disease development in his study conducted on dogs due to a vitamin deficiency (2). Earlier, it was thought that Vit D would only affect calcium and phospor metabolism, however, recently it has been demonstrated that Vit D has receptors on many tissues such as pancreas, breast, lung, gonads, stomach, heart, brain, skin, and lymphocytes (2). Nowadays, Vit D deficiency is pandemic and it is associated with many cancer types, cardiovascular diseases, otoimmune diseases, and infectious diseases (3). There are 2 main types of Vit D (4); ergocalsiferol (Vit D2 ; 25(OH)D2) which is mostly obtained from foods of plant origin and cholecalciferol (Vit D3; 25(OH)D3) which is derived from 7-dehydrocholesterol: a product of cholesterol oxidation in the skin with ultraviole-B radiation effect (4). Vit D3 is the main Vit D for humans (5). Although the metabolisms of Vit D2 and D3 are similar, Vit D3 is more potent than Vit D2 for increasing serum 25(OH)D levels (5).

There is a negative correlation between Vit D and Body Mass Index (BMI) (3). Vit D is a sterol, therefore, the storage rate of Vit D increases in fatty tissues (3, 6). Consequently, Vit D levels in the circulation decreases (3, 6). Also, it is speculated that lower Vit D levels in obese patients may be due to the fact that these people mostly live indoors and have a sedentary life (3, 6).

The aim of this study was to evaluate Vit D levels in Turkish women with BMI > 25 kg/m2.

2. Methods

2.1. Participants

A total number of 31 Turkish women with BMI > 25 kg/m2 were recruited in this study during winter and were divided into 2 groups according to their BMI. Group 1 consisted of subjects with BMI > 25 - 34 kg/m2 and group 2 consisted of subjects with BMI ≥ 35 kg/m2. Participants with thyroid/parathyroid disorders, heart failure, arrhythmias, renal/hepatic dysfunction, uncontrolled hypertension, neoplasm, chronic inflammatory diseases, active infection, connective tissue/ottoimmune diseases, and pregnancy, and patints who were taking medications affecting the endpoints including Vit D preparations and insulin sensitisers were excluded. Written informed consent was taken from all the participants and our local hospital’s Ethics Board approved this study.

2.2. Laboratory Measurements

Venous blood samples were collected from the participants during early morning hours. Blood samples were immediately centrifuged at 1000 rpm for 10 minutes and the upper serum was frozen at -80 degrees Celsius for future use.

Routine biochemical and hormonal parameters were measured using Cobas c501 and C6000 otoanalyzer (Roche Diagnostic, USA).

The Homeostatic Model Assessment (HOMA) was used to quantify the Insulin Resistance (IR). The approximating equation for IR used a fasting plasma sample and was derived by the use of the insulin-glucose product divided by a constant:

HOMA-IR = (Glucose (mg/dL) x Insulin) / 405.

2.3. Vitamin D Assay

High performance liquid chromatography-mass spectrometry (HPLC-MS) method was used to measure the serum level of 25(OH)D following the standards stipulated by NIH (Ultimate 3000 device, Thermo Fisher Scientific Vit D kits, Germany).

All of the blood samples were collected during winter (January-March).

2.4. Statistics

Number cruncher statistical system (NCSS) (Kaysville, Utah, USA 2007) program was used for statistical analysis. Study data were analyzed using descriptive statistical methods such as mean, standard deviation, median, frequency, ratio, minimum, and maximum. Normally distributed quantitative data were analyzed by Student t test and non-normally distributed data were analyzed by Mann Whitney U test. Spearman’s rank correlation was used to test the association of Vit D with other laboratory parameters. P values (two-tailed) lower than 0.05 with 95% confidence level were considered as statistically significant.

3. Results

Group 1 consisted of 15 (46.9%) women with BMI = 25-34kg/m2 and group 2 consisted of 17 (53.1%) women with BMI ≥ 35kg/m2. Laboratory findings of the groups are given in Table 1. Accordingly, age was not statistically different between the groups (36.2 ± 13.46 vs 40.47 ± 15.4, P = 0.41). Although Vit D levels in both groups were below the reference limit which was 25 ng/mL, it was similar between the groups (24.82 ± 13.7 ng/mL vs 23.56 ± 12.31 ng/mL; P = 0.901). Glucose levels were significantly lower in group 1 than group 2 (90.85 ± 13.25 mg/dL vs 118.5 ± 50.55 mg/dL; P = 0.04). Although statistically insignificant, insulin levels were higher in group 2 than group 1 (19,68 ± 7,91 µU/mL vs 17.6 ± 12.02 µU/mL; P = 0.29). Other biochemical markers were similar between the groups. Correlation analysis between Vit D and other parameters is given in Table 2. Accordingly, insulin levels were negatively correlated with Vit D levels (r = -0.631; P = 0.002; P < 0.05). HOMA-IR levels were insignificantly higher in group 2 patients than group 1 (5.10 ± 2.89 vs 4.19 ± 3.35; P = 0.25). HOMA-IR was negatively correlated with Vit D (r = -0.456; P = 0.05).

Table 1.

Laboratory Findings of the Groups

VariablesGroup 1 (BMI < 35), (n = 15)Group 2 (BMI ≥ 35), (n = 17)P Value
Min - MaxMean ± SDMin - MaxMean ± SD
Age15 - 5236.2 ± 13.4617 - 6040.47 ± 15.40.413
Glucose, mg/dL72 - 12490.85 ± 13.2580 - 233118.5 ± 50.550.044a
TSH, µIU/mL0.6 – 4.62.41 ± 1.030.5 - 7.62.56 ± 1.930.321
Insulin, µU/mL3- 44.217.6 ± 12.028.7 - 33.319.68 ± 7.910.292
Cortisol, µg/dL10.9 - 23,415.6 ± 6.785.7 - 20.210.42 ± 5.840.180
Vitamin D, ng/mL8 – 48.624.82 ± 13.78.9 – 49.823.56 ± 12.310.901
TC, mg/dL173 - 230197 ± 24.26117 - 238196.6 ± 49.080.462
HOMA-IR0.6 - 11.84.19 ± 3.351.8 – 11.25.10 ± 2.890.256
Triglyceride, mg/dL61 - 13293.5 ± 35.86109 - 141127.25 ± 15.840.149
HDL, mg/dL35-7348±17,6834 - 6451.25 ± 12.530.773
LDL, mg/dL113,8-144,8130,3±13,5324 – 157.2113.24 ± 53.820.806
Table 2.

Correlation Analysis Between Vitamin D and Other Parameters

VariablesVitamin D
rP Value
Age0.1160.271
Glucose-0.1370.513
TSH-0.2580.258
Insulin-0.6310.002a
Cortisol0.5030.204
BMI-0.0480.911
TC-0.1430.760
Triglyceride-0.2140.645
HDL-0.1570.368
LDL0.0480.911
Homa-IR-0.4560.050b

4. Discussion

The results in this study demonstrated decreased Vit D levels in obese Turkish women and a negative correlation among Vit D and insulin and IR in this group of patients. These findings are compatible with previous studies that exhibited negative correlation among Vit D, obesity, and IR (3, 6).

Our country is prone to Vit D deficiency because it is located on 36 to 42 degrees North latitude (7). And efficient sunshine for Vit D production is observed only in 4 months in the year (7). Besides, it is known that people living in areas more than 35 degrees latitude are prone to inadequate Vit D synthesis (1, 7).

Vit D active metabolites affect target cells through Vit D Receptors (VDR) (8). VDRs are located on more than 30 different tissue cells such as parathyroid, renal, endothelial, myocardial, vascular smooth muscle, skin, lung, pancreas, etc. (8). Vit D is essential for optimal functioning of many organs and tissues (9). Vit D deficiency is correlated with coronary artery disease, heart failure, stroke, diabetes, hypertension, and endothelial dysfunction (10). NHANES III trial demonstrated negative association between serum 25(OH)D3 levels and hypertriglyseridemia, diabetes, hypertension, and obesity (11). Framingham Offspring’s study has, also, revealed higher cardiovascular events in subjects with lower 25(OH)D3 levels after a 5.4 year follow-up (12).

Vit D deficiency is observed during the course of many chronic diseases (13). For example, 1-alpha hydroxilase enzyme activity is diminished during renal failure (13). Therefore, Vit D cannot be converted to its active form and, consequently, parathormone levels are increased (13). Increase in parathormone is associated with a sudden increase of blood pressure and cardiac contractility power which may cause cardiac hypertrophy, myocardial fibrosis, and, eventually, heart failure (13). Human studies have demonstrated that 1,25(OH)D3 inhibits renin synthesis and lowers blood pressure (1). Many observational studies have, also, revealed Vit D deficiency in patients with heart failure (14). Vit D deficiency is, also, associated with increased inflammatory marker levels such as C-reactive protein and interleukin-6 (8). Increased total cholesterol and triglyceride levels and decreased high density lipoprotein and apolipoprotein A-1 levels are found in patients with low vit D levels (14). Minambres et al. showed statistically decresed Vit D levels in patients with familial hyperlipidemia compared to controls and an increase in Vit D levels after replacement treatment (15). A meta-analysis conducted on 65994 patients revealed reverse relation with Vit D levels and cardiovascular and cerebrovascular events (12). Carelli et al. demonstrated the negative correlation between Vit D levels and carotis intima-media thickness (16). Demir et al. evaluated Vit D levels in 87 patients with thoracic aorta dilation and showed significantly lower Vit D levels and higher parathormone levels in the patient group than the controls (17).

There was a significant negative correlation among vit D and serum insulin levels and IR in our study. Animal studies have shown that 1α,25-dihydroxyvitamin D3 stimulates the pancreatic β-cell to secrete insulin, therefore, Vit D deficiency increases IR and the incidence of metabolic syndrome and diabetes (1, 18). Young et al. demonstrated that Vit D deficiency is determinative in coronary calcification development in patients with type 1 diabetes (19). Scott et al. showed IR in Vit D deficient women with polycyctic ovary syndrome (20). Sun et al. revealed that 1 year Vit D supplementation reduced IR in healthy Japanese adults (21).

Many studies have, also, investigated the effect of Vit D supplementation on various clinical situations, however, the results are conflicting (22-25). Eftekhari et al. evaluated the effect of consuming Vit D on glucose metabolism in patients with type 2 diabetes and demonstrated increased insulin secretion without improvement in HbA1c levels and IR (22). Akbarzadeh et al. studied the anti-inflammatory effect of Vit D supplementation in patients with diabetes (23). Vaziri et al. showed that Vit D supplementation during the last trimester of pregnancy is helpful in decreasing perinatal depression rates (24). Vaziri et al, also, published another similar study in which they evaluated the role of Vit D ingestion during pregnancy on the bone mass of both the mother and the child; and the child’s anthropometric measurements, however, could not demonstrate an improvement with Vit D (25).

4.1. Study Limitations

One important limitation of the current study was the relatively small number of participants who were included, therefore, further studies with larger sample sizes are warranted to confirm our findings. We only selected subjects with BMI > 25 kg/m2. Another group of subjects with normal BMI could have been included. However, our aim in this study was to evaluate and compare Vit D levels in obese patients. By this way, our study can be evaluated as being original. On the other hand, we only measured Vit D levels during winter. Another measurement during the summer season is needed.

4.2. Conclusion

In conclusion, obese Turkish women have Vit D deficiency and are prone to IR. Further research is required to determine the potential benefits of vitamin D supplementation for reducing IR in this group of patients.

Acknowledgements

References

  • 1.

    Ku YC, Liu ME, Ku CS, Liu TY, Lin SL. Relationship between vitamin D deficiency and cardiovascular disease. World J Cardiol. 2013;5(9):337-46. [PubMed ID: 24109497]. https://doi.org/10.4330/wjc.v5.i9.337.

  • 2.

    Hochberg Z. Requirements for vitamin D in an indoors culture. Highlights. 2004;12:19-23.

  • 3.

    Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80(6 Suppl):1678S-88S. [PubMed ID: 15585788].

  • 4.

    DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(6 Suppl):1689S-96S. [PubMed ID: 15585789].

  • 5.

    Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011;96(3):E447-52. [PubMed ID: 21177785]. https://doi.org/10.1210/jc.2010-2230.

  • 6.

    Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690-3. [PubMed ID: 10966885].

  • 7.

    Holick MF. Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need? Adv Exp Med Biol. 2008;624:1-15. [PubMed ID: 18348443]. https://doi.org/10.1007/978-0-387-77574-6_1.

  • 8.

    Dong J, Lau CW, Wong SL, Huang Y. Cardiovascular benefits of vitamin D. Sheng Li Xue Bao. 2014;66(1):30-6. [PubMed ID: 24553867].

  • 9.

    Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52(24):1949-56. [PubMed ID: 19055985]. https://doi.org/10.1016/j.jacc.2008.08.050.

  • 10.

    A. Abu El Maaty M, Z. Gad M. Vitamin d deficiency and cardiovascular disease: Potential mechanisms and novel perspectives. J Nutr Sci Vitaminol. 2013;59(6):479-88. https://doi.org/10.3177/jnsv.59.479.

  • 11.

    Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167(11):1159-65. [PubMed ID: 17563024]. https://doi.org/10.1001/archinte.167.11.1159.

  • 12.

    Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-11. [PubMed ID: 18180395]. https://doi.org/10.1161/CIRCULATIONAHA.107.706127.

  • 13.

    Nemerovski CW, Dorsch MP, Simpson RU, Bone HG, Aaronson KD, Bleske BE. Vitamin D and cardiovascular disease. Pharmacotherapy. 2009;29(6):691-708. [PubMed ID: 19476421]. https://doi.org/10.1592/phco.29.6.691.

  • 14.

    Pilz S, Gaksch M, O'Hartaigh B, Tomaschitz A, Marz W. The role of vitamin D deficiency in cardiovascular disease: where do we stand in 2013? Arch Toxicol. 2013;87(12):2083-103. [PubMed ID: 24173581]. https://doi.org/10.1007/s00204-013-1152-z.

  • 15.

    Minambres I, Sanchez-Quesada JL, Sanchez-Hernandez J, Rodriguez J, de Leiva A, Perez A. Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment. Diabetol Metab Syndr. 2014;6(1):7. [PubMed ID: 24450309]. https://doi.org/10.1186/1758-5996-6-7.

  • 16.

    Carrelli AL, Walker MD, Lowe H, McMahon DJ, Rundek T, Sacco RL, et al. Vitamin D deficiency is associated with subclinical carotid atherosclerosis: the Northern Manhattan study. Stroke. 2011;42(8):2240-5. [PubMed ID: 21719770]. https://doi.org/10.1161/STROKEAHA.110.608539.

  • 17.

    Demir M, Uyan U, Melek M. The relationship between vitamin D deficiency and thoracic aortic dilatation. Vasa. 2012;41(6):419-24. [PubMed ID: 23129037]. https://doi.org/10.1024/0301-15626/a000219.

  • 18.

    Chen WR, Qian YA, Chen YD, Shi Y, Yin DW, Wang H, et al. The effects of low vitamin D on coronary artery disease. Heart Lung Circ. 2014;23(4):314-9. [PubMed ID: 24161735]. https://doi.org/10.1016/j.hlc.2013.08.012.

  • 19.

    Young KA, Snell-Bergeon JK, Naik RG, Hokanson JE, Tarullo D, Gottlieb PA, et al. Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care. 2011;34(2):454-8. [PubMed ID: 20978098]. https://doi.org/10.2337/dc10-0757.

  • 20.

    Scott D, Joham A, Teede H, Gibson-Helm M, Harrison C, Cassar S, et al. Associations of Vitamin D with Inter- and Intra-Muscular Adipose Tissue and Insulin Resistance in Women with and without Polycystic Ovary Syndrome. Nutrients. 2016;8(12). [PubMed ID: 27916865]. https://doi.org/10.3390/nu8120774.

  • 21.

    Sun X, Cao ZB, Tanisawa K, Ito T, Oshima S, Higuchi M. Vitamin D supplementation reduces insulin resistance in Japanese adults: a secondary analysis of a double-blind, randomized, placebo-controlled trial. Nutr Res. 2016;36(10):1121-9. [PubMed ID: 27865354]. https://doi.org/10.1016/j.nutres.2016.07.006.

  • 22.

    Eftekhari MH, Akbarzadeh M, Dabbaghmanesh MH, Hasanzadeh J. Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients. Asia Pac J Clin Nutr. 2011;20(4):521-6. [PubMed ID: 22094836].

  • 23.

    Akbarzadeh M, Eftekhari MH, Dabbaghmanesh MH, Hasanzadeh J, Bakhshayeshkaram M. Serum IL-18 and hsCRP correlate with insulin resistance without effect of calcitriol treatment on type 2 diabetes. Iran J Immunol. 2013;10(3):167-76. [PubMed ID: 24076594].

  • 24.

    Vaziri F, Nasiri S, Tavana Z, Dabbaghmanesh MH, Sharif F, Jafari P. A randomized controlled trial of vitamin D supplementation on perinatal depression: in Iranian pregnant mothers. BMC Pregnancy Childbirth. 2016;16(1). https://doi.org/10.1186/s12884-016-1024-7.

  • 25.

    Vaziri F, Dabbaghmanesh MH, Samsami A, Nasiri S, Shirazi PT. Vitamin D supplementation during pregnancy on infant anthropometric measurements and bone mass of mother-infant pairs: A randomized placebo clinical trial. Early Hum Dev. 2016;103:61-8. [PubMed ID: 27513714]. https://doi.org/10.1016/j.earlhumdev.2016.07.011.